Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

"I had asked a moderator if we can better judge whether or not Brilacidin works better with past trial results or Selectivity Index. I lean towards SI since it's promoted often here."

It's true that the SI of brilacidin is much touted here.

Just as often, remdesivir is denigrated here, often by the same people because of what are perceived to be lack-luster results in vivo, especially considering its excellent in vitro results.

In fact, remdesivir's Selectivity Index is significantly higher than brilacidin's at over 1000:

https://www.news-medical.net/news/20200430/Remdesivir-shows-powerful-activity-against-SARS-CoV-2-in-Vitro.aspx

This tells us that SI is actually not a terribly accurate indicator of clinical efficacy (I have discussed one reason why this might be in some of my other posts).

To be fair, previous trial results for brilacidin were not in anti-viral studies so also are not a great predictor of efficacy in COVID-19.

These trial results do however allow us to predict that if the same dose is used as in the previous studies then over 50% of subjects will experience adverse events, some of them serious.